These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12135668)

  • 1. beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.
    Gupta D; Podar K; Tai YT; Lin B; Hideshima T; Akiyama M; LeBlanc R; Catley L; Mitsiades N; Mitsiades C; Chauhan D; Munshi NC; Anderson KC
    Exp Hematol; 2002 Jul; 30(7):711-20. PubMed ID: 12135668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent induction of apoptosis by beta-lapachone in human multiple myeloma cell lines and patient cells.
    Li Y; Li CJ; Yu D; Pardee AB
    Mol Med; 2000 Dec; 6(12):1008-15. PubMed ID: 11474117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.
    Gupta D; Treon SP; Shima Y; Hideshima T; Podar K; Tai YT; Lin B; Lentzsch S; Davies FE; Chauhan D; Schlossman RL; Richardson P; Ralph P; Wu L; Payvandi F; Muller G; Stirling DI; Anderson KC
    Leukemia; 2001 Dec; 15(12):1950-61. PubMed ID: 11753617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.
    Yasui H; Hideshima T; Hamasaki M; Roccaro AM; Shiraishi N; Kumar S; Tassone P; Ishitsuka K; Raje N; Tai YT; Podar K; Chauhan D; Leoni LM; Kanekal S; Elliott G; Munshi NC; Anderson KC
    Blood; 2005 Jul; 106(2):706-12. PubMed ID: 15802527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.
    Dai Y; Landowski TH; Rosen ST; Dent P; Grant S
    Blood; 2002 Nov; 100(9):3333-43. PubMed ID: 12384435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
    Hideshima T; Chauhan D; Hayashi T; Podar K; Akiyama M; Mitsiades C; MItsiades N; Gong B; Bonham L; de Vries P; Munshi N; Richardson PG; Singer JW; Anderson KC
    Cancer Res; 2003 Dec; 63(23):8428-36. PubMed ID: 14679006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
    Nefedova Y; Landowski TH; Dalton WS
    Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
    Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
    Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
    Catley L; Tai YT; Shringarpure R; Burger R; Son MT; Podar K; Tassone P; Chauhan D; Hideshima T; Denis L; Richardson P; Munshi NC; Anderson KC
    Cancer Res; 2004 Dec; 64(23):8746-53. PubMed ID: 15574786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation of p53, induction of Bax and activation of caspases during beta-lapachone-mediated apoptosis in human prostate epithelial cells.
    Choi YH; Kim MJ; Lee SY; Lee YN; Chi GY; Eom HS; Kim ND; Choi BT
    Int J Oncol; 2002 Dec; 21(6):1293-9. PubMed ID: 12429980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of poly(ADP-ribose) polymerase activation attenuates beta-lapachone-induced necrotic cell death in human osteosarcoma cells.
    Liu TJ; Lin SY; Chau YP
    Toxicol Appl Pharmacol; 2002 Jul; 182(2):116-25. PubMed ID: 12140175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of CDK inhibitors (p21(WAF1) and p27(Kip1)) and Bak in the beta-lapachone-induced apoptosis of human prostate cancer cells.
    Don MJ; Chang YH; Chen KK; Ho LK; Chau YP
    Mol Pharmacol; 2001 Apr; 59(4):784-94. PubMed ID: 11259623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.
    Hideshima T; Chauhan D; Schlossman R; Richardson P; Anderson KC
    Oncogene; 2001 Jul; 20(33):4519-27. PubMed ID: 11494147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.
    Uchiyama H; Barut BA; Mohrbacher AF; Chauhan D; Anderson KC
    Blood; 1993 Dec; 82(12):3712-20. PubMed ID: 8260708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The interaction of vascular endothelial growth factor and interleukin-6 in multiple myeloma].
    Zhang L; Chen SL; Chen WM; Liu JW
    Zhonghua Nei Ke Za Zhi; 2005 Feb; 44(2):85-8. PubMed ID: 15840215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
    Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
    Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
    Hideshima T; Chauhan D; Ishitsuka K; Yasui H; Raje N; Kumar S; Podar K; Mitsiades C; Hideshima H; Bonham L; Munshi NC; Richardson PG; Singer JW; Anderson KC
    Oncogene; 2005 Apr; 24(19):3121-9. PubMed ID: 15735676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major contribution of the multidrug transporter P-glycoprotein to reduced susceptibility of poly(ADP-ribose) polymerase-1 knock-out cells to doxorubicin action.
    Wesierska-Gadek J
    J Cell Biochem; 2005 Aug; 95(5):1012-28. PubMed ID: 15861398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.